Biotechnology Business
Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
Published in Hospital Law Weekly, June 26th, 2008
Targeted Genetics Corporation (NASDAQ:TGEN) announced that positive results of a Phase 1/2 clinical study demonstrate that tgAAC94, its investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve disease symptoms in inflammatory arthritis patients refractory to other therapies, including systemic TNF antagonists. Full results of the study were presented here today during an oral presentation at the Annual European Congress of Rheumatology (EULAR).
The Phase 1/2 study evaluated multiple doses of tgAAC94 administered directly to affected joints with or without concurrent...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Law Weekly
Source: Hospital Law Weekly (2008-06-26)
More Articles from Hospital Law Weekly
- ALM Media, Inc.
ALM Events Announces Fifth Annual Cosmeceuticals Conference - American Institute of Physics
Highlights of upcoming acoustics meeting -- June 30 to July 4 in Paris, France - Centre for Addiction and Mental Health
Save $1 billion and 800 lives - Hip Fracture
New hip fracture research reported from Institute for Health Policy - Human Reproduction
Reports outline human reproduction research from Uppsala University - Leukemia
W. Paul Bowman Named Department Chair of Pediatrics at Texas College of Osteopathic Medicine - More from this issue of Hospital Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
